Log in

Relevant bibliographies by topics / Hypercholestermia / Journal articles

To see the other types of publications on this topic, follow the link: Hypercholestermia.

Journal articles on the topic 'Hypercholestermia'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Hypercholestermia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Visavadiya, Nishant P., and A. V. R. L. Narasimhacharya. "AsparagusRoot Regulates Cholesterol Metabolism and Improves Antioxidant Status in Hypercholesteremic Rats." Evidence-Based Complementary and Alternative Medicine 6, no. 2 (2009): 219–26. http://dx.doi.org/10.1093/ecam/nem091.

Full text

Abstract:

Hyperlipidemia/hypercholesteremia are major risk factors for atherosclerosis and cardiovascular diseases. Root ofAsparagus racemosus(AR) is widely used in Ayurvedic system of medicine in India and is known for its steroidal saponin content. This study was designed to investigate the hypocholesteremic and antioxidant potential of AR root in both normo- and hypercholesteremic animals. Normal and hypercholesteremic male albino rats were administered with root powder of AR (5 and 10 g% dose levels) along with normal and hypercholesteremic diets, respectively, for a duration of 4 weeks. Plasma and hepatic lipid profiles, fecal sterol, bile acid excretion and hepatic antioxidant activity were assessed. Inclusion of AR root powder in diet, resulted in a dose-dependant reduction in plasma and hepatic lipid profiles, increased fecal excretion of cholesterol, neutral sterol and bile acid along with increases in hepatic HMG-CoA reductase activity and bile acid content in hypercholesteremic rats. Further, AR root also improved the hepatic antioxidant status (catalase, SOD and ascorbic acid levels). No significant changes in lipid and antioxidant profiles occurred in the normocholesteremic rats administered with AR root powder. AR root appeared to be useful as a dietary supplement that offers a protection against hyperlipidemia/hypercholesteremia in hypercholesteremic animals. The results of the present study indicate that the potent therapeutic phyto-components present in AR root i.e. phytosterols, saponins, polyphenols, flavonoids and ascorbic acid, could be responsible for increased bile acid production, elimination of excess cholesterol and elevation of hepatic antioxidant status in hypercholesteremic conditions.

APA, Harvard, Vancouver, ISO, and other styles

2

Li, Nan F., Hong M. Wang, Jin Yang, Ling Zhou, Xiao G. Yao, and Jing Hong. "Serum uric acid is associated with metabolic risk factors for cardiovascular disease in the Uygur population." Applied Physiology, Nutrition, and Metabolism 34, no. 6 (December 2009): 1032–39. http://dx.doi.org/10.1139/h09-101.

Full text

Abstract:

The prevalence of hyperuricemia is low in Uygurs, who have a high prevalence of cardiovascular risk factors such as hypertension, overweight–obesity, dyslipidemia, hyperglycemia, and insulin resistance (IR). This study sought to investigate the relationships between serum uric acid (UA) and these risk factors in this population. A cross-sectional study was conducted in Uygurs (859 males, 1268 females) aged 20 to 70 years. Demographic data, systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), and fasting and postprandial blood were obtained, and biological measurements were determined. The mean of BMI, SBP, DBP, total cholesterol, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), triglycerides, fasting blood glucose, fasting insulin, and homeostasis model assessment insulin resistance index (HOMA-IR), and the prevalence of hypertension, IR, hyperglycemia, overweight–obesity, hypercholesteremia, hyper-LDL-c, and hypertriglyceridemia increased with UA but the prevalence of hypo-HDL-c decreased (p < 0.05). Logistic regression analysis showed that the odds ratios for IR, overweight–obesity, hypercholesteremia, hyper-LDL-c, and hypertriglyceridemia against the lowest UA group increased but decreased for hypo-HDL-c (p < 0.05). The UA in the hypo-HDL-c group was lower than that of the controls; the prevalence of hypo-HDL-c in hyperuricemia subjects was lower than in those with normal UA (p < 0.05). But the opposite results were observed between overweight–obesity, hyperglycemia, IR, hypercholesteremia, hypertriglyceridemia, and hyper-LDL-c and correspondence controls, respectively (p < 0.05). In Uygur, elevated UA is associated with overweight–obesity, hypercholesteremia, hyper-LDL-c, hypertriglyceridemia, hyperglycemia, and IR. The HDL-c level significantly increases with UA, whereas the prevalence of hypo-HDL-c decreases. Further studies are needed to clarify why UA is positively correlated to HDL-c.

APA, Harvard, Vancouver, ISO, and other styles

3

Kamalova, Aelita A. "Diet Therapy in Children with Hypercholesteremia." Current Pediatrics 19, no. 4 (September 19, 2020): 309–15. http://dx.doi.org/10.15690/vsp.v19i4.2140.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

LEWIS, S. "P514 Hypercholesteremia induces baroreceptro reflex dysfunction." European Heart Journal 24, no. 5 (March 2003): 81. http://dx.doi.org/10.1016/s0195-668x(03)93952-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Dietrich, Hans H. "Apolipoprotein E in Hypercholesteremia and Beyond." Stroke 38, no. 7 (July 2007): 2036. http://dx.doi.org/10.1161/strokeaha.107.489856.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

NAKAI, TSUGUHIKO. "Familial hypercholesteremia complicated by nephrotic syndrome." Nihon Naika Gakkai Zasshi 79, no. 8 (1990): 1079–80. http://dx.doi.org/10.2169/naika.79.1079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

HURLEY, D. "Hypercholesteremia induces enhanced circulating inflammatory activity." American Journal of Hypertension 17, no. 5 (May 2004): S242. http://dx.doi.org/10.1016/j.amjhyper.2004.03.648.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Nichols, E. H., and M. R. Jaff. "Hypercholesteremia, Hypertension, and Antiplatelet Therapy in PAD." MD Conference Express 13, no. 19 (December 1, 2013): 31. http://dx.doi.org/10.1177/155989771319015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kiyohara, Keiji, Kazuhiro Tamura, Masahiro Shimada, and Jyuji Nisi. "A case of familial hypercholesteremic xanthomatosis." Orthopedics & Traumatology 37, no. 3 (1989): 1247–49. http://dx.doi.org/10.5035/nishiseisai.37.1247.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Klose, Gerald. "Der gesunde Patient mit Hypercholesterin�mie." Medizinische Klinik 100, no. 2 (February 2005): 99–106. http://dx.doi.org/10.1007/s00063-005-1003-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Kumawat, Vinod Bihari, Surendra Kumar Sharma, Uttam Kumar Sharma, and Sudhir Sharma. "Effect of trikatu compound in hypercholesteremia- a clinical study." Environment Conservation Journal 16, no. 1&2 (June 12, 2015): 57–61. http://dx.doi.org/10.36953/ecj.2015.161209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Tokura, T. "Changes in Bruch's Membrane in Experimental Hypercholesteremia in Rats." Japanese Journal of Ophthalmology 43, no. 4 (July 8, 1999): 337–38. http://dx.doi.org/10.1016/s0021-5155(99)00055-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

BARTON, M. "Hypercholesteremia induces cardiac concentric remodeling in the guinea pig." American Journal of Hypertension 17, no. 5 (May 2004): S165—S166. http://dx.doi.org/10.1016/j.amjhyper.2004.03.434.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Nagaraj, Lavanya, and Naveen Kumar Madalageri. "A comparative study of metabolic side effects of risperidone and olanzapine in the treatment of schizophrenia." International Journal of Basic & Clinical Pharmacology 8, no. 11 (October 22, 2019): 2561. http://dx.doi.org/10.18203/2319-2003.ijbcp20194803.

Full text

Abstract:

ABSTRACTBackground: Schizophrenia is one of most serious chronic psychiatric disorder, which affects about 1% of population. Treatment of schizophrenia comprises of typical antipsychotics and or atypical antipsychotics. Typical antipsychotics like haloperidol have extrapyramidal side effects which limit their use in chronic cases. Atypical antipsychotics though have better treatment response, they have metabolic side effects like hypercholesteremia, hypertriglyceridemia and hyperglycaemia. As there is paucity of data in Indian population the present study has been taken up to compare the metabolic side effects of risperidone and olanzapine in the treatment of schizophrenic patients in a tertiary care hospital.Methods: It was a comparative study conducted on 60 patients of Schizophrenia for one year in a tertiary care hospital. The study subjects were randomly assigned into 2 groups of 30 patients each, where group 1 were treated with atypical antipsychotic drug risperidone and group 2 with Olanzapine and both groups received the treatment for one year. Metabolic side effects like hypercholesteremia, hypertriglyceridemia and hyperglycaemia were evaluated and compared over a period of one year.Results: Both risperidone and olanzapine were associated with comparable baseline to endpoint increase in metabolic side effects. However, risperidone treated subjects had significantly less metabolic side effects compared to olanzapine.Conclusions: Apart from total cholesterol and triglycerides, other metabolic side effects were less in risperidone treated patients than olanzapine treated patients.

APA, Harvard, Vancouver, ISO, and other styles

15

MURTY, Devarakonda, Enjamoori RAJESH, Doonaboina RAGHAVA, Tangaraj Vijaya RAGHAVAN, and Mukanthan Karupiah Munirajan SURULIVEL. "Hypolipidemic Effect of Arborium Plus in Experimentally Induced Hypercholestermic Rabbits." YAKUGAKU ZASSHI 130, no. 6 (June 1, 2010): 841–46. http://dx.doi.org/10.1248/yakushi.130.841.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Elbadawi, Ayman, Islam Y. Elgendy, Mohamed Omer, Mohamed Abdelazeem, Vijay Nambi, Chayakrit Krittanawong, Ravi S. Hira, Jacqueline Tamis-Holland, Christie Ballantyne, and Hani Jneid. "Outcomes of Acute Myocardial Infarction in Patients with Familial Hypercholesteremia." American Journal of Medicine 134, no. 8 (August 2021): 992–1001. http://dx.doi.org/10.1016/j.amjmed.2021.03.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

M, Lekeshmanaswamy, Anusiya Devi K, and Vasuki C.A. "BIOCHEMICAL CHANGES OF MERCURY CHLORIDE ON BLOOD METABOLITE LEVELS OF A FRESHWATER FISH, LABEO ROHITA." Kongunadu Research Journal 3, no. 2 (December 30, 2016): 94–96. http://dx.doi.org/10.26524/krj154.

Full text

Abstract:

Rohu (Labeo rohita) is a fish of the carp family Cyprinidae, found commonly in rivers and fresh water lakes in and around South Asia and South - East Asia. The freshwater fish Labeo rohita were exposed to Mercury chloride (0.25 ppm) for 10, 20 and 30 days and its effect on blood – bio chemical properties in the form of hyperglycemia, hypoproteinemia and hypercholesteromia. The results of the present study that the blood – biochemical changes may lead to the fish morbidity and mortality.

APA, Harvard, Vancouver, ISO, and other styles

18

Fan, Jing, Caicui Ding, Weiyan Gong, Fan Yuan, Yanning Ma, Ganyu Feng, Chao Song, and Ailing Liu. "The Relationship between Leisure-Time Sedentary Behaviors and Metabolic Risks in Middle-Aged Chinese Women." International Journal of Environmental Research and Public Health 17, no. 19 (September 30, 2020): 7171. http://dx.doi.org/10.3390/ijerph17197171.

Full text

Abstract:

The prevalence of metabolic diseases has increased over the past few decades, and epidemiological studies suggest that metabolic diseases may be associated with lifestyle. The purpose of the present study was to investigate the relationship between leisure-time sedentary behaviors (LTSBs) and metabolic risks in middle-aged women in China. Data came from the China National Nutrition and Health Surveillance (CNNHS) in 2010–2012. A total of 2643 women aged 46 to 53 years were involved. Multiple linear regression was used to examine the association of leisure-time sedentary duration (LTSD) with total cholesterol (TC), triglyceride (TG), waist circumference (WC), and body mass index (BMI). Restrictive cubic splines (RCS) were used to plot the curves between LTSD and the risk of metabolic diseases. Region, education, income, alcohol consumption, exercise, daily energy intake, and fat energy ratio were adjusted for all models. After adjusting for potential influencing factors, the results of multiple linear regression showed that for each additional hour increase in LTSD, TC and TG increased by 0.03 mmol/L and 0.04 mmol/L, respectively. The results of RCS curves showed that the risks of MetS (p for trend = 0.0276), obesity (p for trend = 0.0369), hypertension (p for trend = 0.0062), and hypercholesteremia (p for trend = 0.0033) increased with the increase in LTSD. LTSB was associated with the risks of MetS, obesity, hypertension, and hypercholesteremia in middle-aged women. Reducing LTSD may be an effective way of preventing metabolic diseases in middle-aged women.

APA, Harvard, Vancouver, ISO, and other styles

19

Cottin, Yves, Marc Kollum, Frank D. Kolodgie, Rosanna C. Chan, Han-Soo Kim, Yoram Vodovotz, Renu Virmani, Ron Waksman, and Hamid Yazdi. "Intravascular radiation accelerates atherosclerotic lesion formation of hypercholesteremic rabbits." Cardiovascular Radiation Medicine 2, no. 4 (October 2001): 231–40. http://dx.doi.org/10.1016/s1522-1865(02)00129-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

SARAVANAN, Selvaraj, Ramasundaram SRIKUMAR, Sundaramahalingam MANIKANDAN, Narayanaperumal JEYA PARTHASARATHY, and Rathinasamy SHEELA DEVI. "Hypolipidemic Effect of Triphala in Experimentally Induced Hypercholesteremic Rats." YAKUGAKU ZASSHI 127, no. 2 (February 1, 2007): 385–88. http://dx.doi.org/10.1248/yakushi.127.385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Verma, Isha, Antonio Fernandez, and Paul Thompson. "FAMILIAL HYPERCHOLESTEREMIA: WHEN STATINS, EZETIMIBE & PCSK9 INHIBITORS ARE NOT ENOUGH." Journal of the American College of Cardiology 71, no. 11 (March 2018): A2439. http://dx.doi.org/10.1016/s0735-1097(18)32980-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Didia, S. Claudia. "PCSK9-Inhibitors: A Review of a Novel Approach in Hypercholesteremia Management." Medical Science Review 1 (2014): 1–6. http://dx.doi.org/10.12659/msrev.890836.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Verma, Isha, Paul D. Thompson, and Antonio B. Fernandez. "Familial Hypercholesteremia: When Statins, Ezetimibe & PCSK9 Inhibitors Are Not Enough." Journal of Clinical Lipidology 12, no. 2 (March 2018): 545. http://dx.doi.org/10.1016/j.jacl.2018.03.043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Valentine, V. G., L. Seoane, D. M. Fuchs, S. G. LaPlace, G. A. Lombard, and D. E. Taylor. "Potential benefits of treating hypercholesteremia and hypertension in lung allograft recipients." Journal of Heart and Lung Transplantation 24, no. 2 (February 2005): S170. http://dx.doi.org/10.1016/j.healun.2004.12.105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

MUNDAY, J. "Hypercholesteremia-induced changes in left ventricular geometry in the guinea pig." American Journal of Hypertension 17, no. 5 (May 2004): S168. http://dx.doi.org/10.1016/j.amjhyper.2004.03.441.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Zhang, Haoqiang, Rong Huang, Sai Tian, Ke An, Wenwen Zhu, Jijing Shi, Wuyou Cao, and Shaohua Wang. "The CC Genotype of Insulin-Induced Gene 2 rs7566605 Is a Protective Factor of Hypercholesteremia Susceptible to Mild Cognitive Impairment, Especially to the Executive Function of Patients with Type 2 Diabetes Mellitus." BioMed Research International 2020 (June 10, 2020): 1–7. http://dx.doi.org/10.1155/2020/4935831.

Full text

Abstract:

Backgrounds and Aims. Insulin-induced gene 2 (INSIG-2) is closely related to hypercholesteremia, which is a well-recognized risk factor of mild cognitive impairment (MCI) in type 2 diabetes mellitus (T2DM). We aim to investigate the association between promoter of the INSIG-2 rs7566605 single-nucleotide polymorphism (SNP) and T2DM with MCI. Methods. 233 T2DM patients with MCI or without MCI were recruited. Baseline data and genotype frequency were compared between MCI and non-MCI groups. Demographic parameters and neuropsychological tests results were analyzed among patients with different genotypes. Further correlation and regression analysis were conducted to find the association between cognition and cholesterol. Results. Despite no significant statistical difference was detected, we observed higher levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL) in patients with MCI than those without MCI. In addition, we observed higher TC and LDL levels in patients with GG or GC genotypes than those with CC genotype (P<0.001, P=0.004, or P<0.001, P=0.002). Interestingly, increased MoCA and decreased TMTB scores were found in patients with CC genotype, compared to those with GG or CG genotype (P=0.009, P=0.024, or P=0.005, P=0.109). Moreover, partial correlation (P=0.030 and P=0.004, respectively) and multiple linear regression (P=0.030 and P=0.005, respectively) showed that TC and LDL levels are associated with the TMTB score, indicating the executive function. Conclusions. CC genotype of INSIG-2 rs7566605 may be a protective factor of hypercholesteremia susceptible to MCI, especially to the executive function of T2DM. This trial is registered with ChiCTROCC15006060.

APA, Harvard, Vancouver, ISO, and other styles

27

R.L. Narasimhacharya, AV, and NP Visavadiya. "Hypolipidemic and antioxidant activities of Asparagus racemosus in hypercholesteremic rats." Indian Journal of Pharmacology 37, no. 6 (2005): 376. http://dx.doi.org/10.4103/0253-7613.19074.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Yakimenko, O., and Ie Maznichenko. "COMPLEX HYPOLIPIDEMIC THERAPY OF PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS AND FAMILIAL HYPERCHOLESTEREMIA." Bulletin of Problems Biology and Medicine 1, no. 2 (2019): 207. http://dx.doi.org/10.29254/2077-4214-2019-1-2-149-207-211.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Hyvärinen, Lea. "FLUORESCENCE CINEANGIOGRAPHIC AND HISTOLOGICAL STUDIES ON THE RABBIT EYE DURING EXPERIMENTAL HYPERCHOLESTEREMIA." Acta Ophthalmologica 46, no. 1 (May 27, 2009): 57–70. http://dx.doi.org/10.1111/j.1755-3768.1968.tb02495.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Miyayama, Takeshi, Shin-ichiro Miura, Tomo Komaki, Takashi Kuwano, Joji Morii, Hiroaki Nishikawa, and Keijiro Saku. "Acute Myocardial Infarction in a 26-Year-Old Patient With Familial Hypercholesteremia." Journal of Clinical Medicine Research 8, no. 7 (2016): 562–65. http://dx.doi.org/10.14740/jocmr2596w.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Jha, Niharika, and Vanya Narayan. "Multiple giant tuberous xanthomas with type IIa hypercholesteremia in a young male." Indian Journal of Dermatopathology and Diagnostic Dermatology 7, no. 1 (2020): 38. http://dx.doi.org/10.4103/ijdpdd.ijdpdd_40_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

RANA, MOHAMMAD MOHSIN, BADAR BASHIR, MUHAMMAD SAEED AKHTAR, and Abaid Ur-Rehman. "TYPE 2 DIABETICS." Professional Medical Journal 14, no. 02 (September 6, 2007): 337–43. http://dx.doi.org/10.29309/tpmj/2007.14.02.4900.

Full text

Abstract:

Objective: To find the relationship between the serum cholesterol andtriglyceroid in type 2 diabetics with different parameters of obesity. Design: Descriptive study. Setting: Al-ShifaMetabolic Center Faisalabad. Period: From January 2003 to June 2005. Material and methods: A total of 2034patients, who fulfill the inclusion criteria were included in this study. Out of these patients 1188 females and 846 males,patients presented to the metabolic center for lipids screening. Body parameters i.e. weight, height, waist and hipcircumference and blood pressure. BMI and WHR were calculated as per standard. Fasting serum cholesterol andtriglyceroid were tested on capillary blood by GCT meter. Results: There is a sharp and definite increase in the % ofpatients having > 200 mg/dl total cholesterol after 10 years of DM, from 34-36% to 59%. More patients in above 50 agegroup had higher than 200-mg/dl-cholesterol i.e.38%, 50% and 36% than below 50 years i.e. 30% and 24%. Serumtriglyceroid levels in the middle range of 150-300 had a definite ascending relationship with increasing BMI, 17%, 47%and 71% respectively. High WHR in both sexes had the strongest relation with high serum cholesterol both in 150-200and >200 mg/dl range, 37% and 41% and 40 and 41% respectively. Serum triglyceroid was definitely higher in patientswith high WHR in both sexes in 150-300 ranges. Conclusions: It is clearly evident that the duration of hyperglycemia,age at onset of DM and the central obesity, all increases the chances of having hypercholesteremia. It is again evidentthat so many other factors influence the incidence of hypercholesteremia; screening is the only way to pick thesepatients. Every patient with any component of the Metabolic Syndrome must be screened for other components foroptimal stratification of the coronary risk factors.

APA, Harvard, Vancouver, ISO, and other styles

33

Visavadiya, Nishant P., and A. V. R. L. Narasimhacharya. "Hypocholesteremic and antioxidant effects of Withania somnifera (Dunal) in hypercholesteremic rats." Phytomedicine 14, no. 2-3 (February 2007): 136–42. http://dx.doi.org/10.1016/j.phymed.2006.03.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Godal, H. C., J. C. Lund, and E. Sivertssen. "LIPIDS AND LIPOPROTEINS IN SERUM IN CASES OF FAMILIAL ESSENTIAL HYPERCHOLESTEREMIA AND XANTHOMATOSIS." Acta Medica Scandinavica 156, S319 (April 24, 2009): 125–34. http://dx.doi.org/10.1111/j.0954-6820.1956.tb06306.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Barrios, Vivencio, and Carlos Escobar. "Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk." Expert Review of Clinical Pharmacology 14, no. 7 (May 24, 2021): 793–806. http://dx.doi.org/10.1080/17512433.2021.1925539.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Drew-Nord, Dana C., OiSaeng Hong, Erika S. Froelicher, Phyllis Berryman, and Eileen Lukes. "Cardiovascular Risk Factors among Career Firefighters." AAOHN Journal 57, no. 10 (October 2009): 415–24. http://dx.doi.org/10.1177/216507990905701004.

Full text

Abstract:

Sudden cardiac death is the leading cause of on-duty death among firefighters. Determining firefighters' risk of cardiovascular death or all-cause mortality, cardiovascular risk factor profiles, and energy demands while firefighting may aid in understanding why this occupational group is at risk for on-duty sudden cardiac death. A literature review conducted between 2006 and 2009 did not demonstrate that firefighters are at increased risk of all-cause death compared to the general population. In addition, cardiovascular risk profiles of firefighters are similar to those of the general population. Firefighters may be part of the national obesity epidemic; their hypertension and hypercholesteremia often are not diagnosed or are undertreated. The combination of personal cardiovascular risk factors and extreme physical work demands may contribute to sudden cardiac death in this population.

APA, Harvard, Vancouver, ISO, and other styles

37

Shalaby, M., Gehan Ghoniem, M. Domma, and A. Elias. "Protective Effect of Turmeric and Garlic Powder on hypercholesterlemia Level in Rats." Journal of Food and Dairy Sciences 7, no. 7 (July 1, 2016): 355–62. http://dx.doi.org/10.21608/jfds.2016.46022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

KONTTINEN, AARNE. "The Effect of Triparanol on the Serum Lipid Pattern in Hypercholesteremic Patients." Acta Medica Scandinavica 171, no. 6 (April 24, 2009): 753–57. http://dx.doi.org/10.1111/j.0954-6820.1962.tb04241.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Awad, A. "Assessment of Licorice (Glycyrrhiza glabra l.) Aqueous Extract on Lipid Profile in Hypercholestermic Rats." Journal of Agricultural Chemistry and Biotechnology 8, no. 2 (February 1, 2017): 21–26. http://dx.doi.org/10.21608/jacb.2017.38422.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Adlersberg, David, Leon Hellman, and Robert S. Rosenfeld. "Isotope Studies on Exogenous and Endogenous Cholesterol Metabolism in Normo- and Hypercholesteremic Man." Acta Medica Scandinavica 154, S312 (April 24, 2009): 737–41. http://dx.doi.org/10.1111/j.0954-6820.1956.tb17081.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Contaldo, C., A. Elsherbiny, D. Högger, S. Vetter, N. Lindenblatt, M. Calcagni, and P. Giovanoli. "Erythropoietin improves wound healing by increasing red blood cell perfusion in hypercholesteremic mice." Journal of Plastic, Reconstructive & Aesthetic Surgery 62, no. 6 (June 2009): 834S. http://dx.doi.org/10.1016/j.bjps.2009.02.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Luther, Th, S. Albrecht, M. Kotzsch, H. Grossmann, and M. Müller. "Detecting of tissue factor in plasma from patients with thrombembolic diseases and hypercholesteraemia." Thrombosis Research 65 (January 1992): S188. http://dx.doi.org/10.1016/0049-3848(92)90689-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Bardia, A., and G. Garg. "Mipomersen For Treatment Of Hypercholesteremia: Evidence Review And Meta Analytic Evaluation Of Randomized Controlled Trials." Value in Health 18, no. 3 (May 2015): A132. http://dx.doi.org/10.1016/j.jval.2015.03.771.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Naik, Aleš Belič Adviti. "Analysis of the Cholesterol Biosynthesis Feedback Control and its Consequences for the Hypercholesteremia Treatment Strategies." IFAC Proceedings Volumes 45, no. 2 (2012): 624–28. http://dx.doi.org/10.3182/20120215-3-at-3016.00111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Huige, M. C., J. J. R. M. Bonnier, H. J. Rila, L. J. Jansen, K. te VElde, A. J. te Rijdt, P. de Weerd, and P. A. Leijten. "Efficacy and safety of pravastatin in Dutch patients with hypercholesteremia and additional coronary risk factors." Atherosclerosis 115 (June 1995): S128. http://dx.doi.org/10.1016/0021-9150(95)96739-f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Ezratty, Ellen J., Claire Bertaux, Eugene E. Marcantonio, and Gregg G. Gundersen. "Clathrin mediates integrin endocytosis for focal adhesion disassembly in migrating cells." Journal of Cell Biology 187, no. 5 (November 30, 2009): 733–47. http://dx.doi.org/10.1083/jcb.200904054.

Full text

Abstract:

Focal adhesion disassembly is regulated by microtubules (MTs) through an unknown mechanism that involves dynamin. To test whether endocytosis may be involved, we interfered with the function of clathrin or its adaptors autosomal recessive hypercholesteremia (ARH) and Dab2 (Disabled-2) and found that both treatments prevented MT-induced focal adhesion disassembly. Surface labeling experiments showed that integrin was endocytosed in an extracellular matrix–, clathrin-, and ARH- and Dab2-dependent manner before entering Rab5 endosomes. Clathrin colocalized with a subset of focal adhesions in an ARH- and Dab2-dependent fashion. Direct imaging showed that clathrin rapidly accumulated on focal adhesions during MT-stimulated disassembly and departed from focal adhesions with integrin upon their disassembly. In migrating cells, depletion of clathrin or Dab2 and ARH inhibited focal adhesion disassembly and decreased the rate of migration. These results show that focal adhesion disassembly occurs through a targeted mechanism involving MTs, clathrin, and specific clathrin adaptors and that direct endocytosis of integrins from focal adhesions mediates their disassembly in migrating cells.

APA, Harvard, Vancouver, ISO, and other styles

47

Kirkorowicz, JM, P. Sapukotana, PV De Silva, M. Noda, JS De Oliveira, and T. Østbye. "Work-Related Stress and Substance Use as Risk Factors for Chronic Disease Among Three-Wheel Drivers in Galle, Sri Lanka: A Qualitative Study." International Journal of Occupational Safety and Health 3, no. 2 (February 10, 2014): 21–24. http://dx.doi.org/10.3126/ijosh.v3i2.7662.

Full text

Abstract:

Background: Motor three-wheel drivers provide an important means of transportation in Sri Lanka, comprising 15% of motorized road vehicles. Although three-wheel driving is a widespread occupation for Sri Lankan men, little is known about their general health or risk factors.Objectives: This paper investigates chronic illnesses and risk factors for such illnesses in a sample of 33 three-wheel drivers in Galle, Sri Lanka.Methods: A qualitative investigation was conducted between June and August 2012. 20 three-wheel drivers participated in 60-minute semi-structured interviews, and 13 participated in semi- structured focus groups related to their work-related health concerns.Results: Illness reported included musculoskeletal pain, hypercholesteremia, hypertension, and diabetes. Participants identified work-related stress and substance abuse as risk factors.Conclusions: Participants described a cycle of work related stress, substance use, and chronic illness. Community-based education on the risks of substance use and alternative means of coping may be an effective intervention for these workers. DOI: http://dx.doi.org/10.3126/ijosh.v3i2.7662

APA, Harvard, Vancouver, ISO, and other styles

48

CHISAKA, TAKESHI, HISASHI MATSUDA, YASUSHI KUBOMURA, MICHIHIKO MOCHIZUKI, JOHJI YAMAHARA, and HAJIME FUJIMURA. "The effect of crude drugs on experimental hypercholesteremia: Mode of action of (-)-epigallocatechin gallate in tea leaves." CHEMICAL & PHARMACEUTICAL BULLETIN 36, no. 1 (1988): 227–33. http://dx.doi.org/10.1248/cpb.36.227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Weng, Pei-Hsuan, Jen-Hau Chen, Ta-Fu Chen, Yu Sun, Li-Li Wen, Ping-Keung Yip, Yi-Min Chu, and Yen-Ching Chen. "P3-253: Interactions between ApoE ε4 status and hypercholesteremia on response to acetylcholinesterase inhibitor in Alzheimer's disease." Alzheimer's & Dementia 11, no. 7S_Part_16 (July 2015): P728. http://dx.doi.org/10.1016/j.jalz.2015.06.1626.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Loria, Roger M., and David A. Padgett. "α-Linolenic acid prevents the hypercholesteremic effects of cholesterol addition to a corn oil diet." Journal of Nutritional Biochemistry 8, no. 3 (March 1997): 140–46. http://dx.doi.org/10.1016/s0955-2863(97)00011-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!